Trial Profile
To assess Tofacitinib efficacy and safety and drug survival in patients with Rheumatoid Arthritis; A Turkbio Registry
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Jun 2022
Price :
$35
*
At a glance
- Drugs Tofacitinib (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Pfizer
- 04 Jun 2022 Results presented at the 23rd Annual Congress of the European League Against Rheumatism
- 24 Oct 2018 Results presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
- 24 Oct 2018 Results assessing the effect of cigarette smoking on the response and drug survival for tofacitinib in RA (n=115) presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting